Article
Exploring the crosstalk between the FGF/FGFR pathway and tumor microenvironment in clear cell renal cell carcinoma
2025-05-07
Abstract excerpt
<title>Abstract</title> <p><bold>Background:</bold> In the phase 3 CLEAR study, lenvatinib plus pembrolizumab showed improved efficacy versus sunitinib for patients with clear cell renal cell carcinoma (ccRCC). Previous preclinical studies demonstrated that lenvatinib attenuated tumor-associated macrophage (TAM) infiltration into tumor tissues by inhibiting fibroblast growth factor receptor (FGFR). However, the r...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- db99ccb8-df2c-586c-9ae6-0fdfda35d118
- DOI
- 10.21203/rs.3.rs-6461270/v1
